The Immunosuppressant FTY720 Prolongs Survival in a Mouse Model of Diet-induced Coronary Atherosclerosis and Myocardial Infarction

Overview

Journal J Cardiovasc Pharmacol

Date 2014 Feb 11

PMID 24508946

Citations 22

Authors

Guanying Wang

Roy Y Kim

Isabella Imhof

Norman Honbo

Fu Sang Luk

Kang Li

Nikit Kumar

Bo-Qing Zhu

Delphine Eberle

Daniel Ching

Joel S Karliner

Robert L Raffai

Affiliations

Soon will be listed here.

Abstract

FTY720, an analogue of sphingosine-1-phosphate, is cardioprotective during acute injury. Whether long-term FTY720 affords cardioprotection is unknown. Here, we report the effects of oral FTY720 on ischemia/reperfusion injury and in hypomorphic apoE mice deficient in SR-BI receptor expression (ApoeR61(h/h)/SRB1(-/- mice), a model of diet-induced coronary atherosclerosis and heart failure. We added FTY720 (0.3 mg·kg(-1)·d(-1)) to the drinking water of C57BL/6J mice. After ex vivo cardiac ischemia/reperfusion injury, these mice had significantly improved left ventricular (LV) developed pressure and reduced infarct size compared with controls. Subsequently, ApoeR61(h/h)/SRB1(-/-) mice fed a high-fat diet for 4 weeks were treated or not with oral FTY720 (0.05 mg·kg(-1)·d(-1)). This sharply reduced mortality (P < 0.02) and resulted in better LV function and less LV remodeling compared with controls without reducing hypercholesterolemia and atherosclerosis. Oral FTY720 reduced the number of blood lymphocytes and increased the percentage of CD4+Foxp3+ regulatory T cells (Tregs) in the circulation, spleen, and lymph nodes. FTY720-treated mice exhibited increased TGF-β and reduced IFN-γ expression in the heart. Also, CD4 expression was increased and strongly correlated with molecules involved in natural Treg activity, such as TGF-β and GITR. Our data suggest that long-term FTY720 treatment enhances LV function and increases longevity in mice with heart failure. These benefits resulted not from atheroprotection but from systemic immunosuppression and a moderate reduction of inflammation in the heart.

Citing Articles

M2 Macrophage Exosomes Reverse Cardiac Functional Decline in Mice with Diet-Induced Myocardial Infarction by Suppressing Type 1 Interferon Signaling in Myeloid Cells.

Ng M, Gao A, Phu T, Vu N, Raffai R bioRxiv. 2024; .

PMID: 39345592 PMC: 11429744. DOI: 10.1101/2024.09.13.612924.

SR-B1-/-ApoE-R61h/h Mice Mimic Human Coronary Heart Disease.

Starsichova A Cardiovasc Drugs Ther. 2023; 38(6):1123-1137.

PMID: 37273155 PMC: 10240136. DOI: 10.1007/s10557-023-07475-8.

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model.

Najarzadegan N, Madani M, Etemadifar M, Sedaghat N PLoS One. 2022; 17(12):e0278488.

PMID: 36477491 PMC: 9728862. DOI: 10.1371/journal.pone.0278488.

Fingolimod does not prevent syndecan-4 shedding from the endothelial glycocalyx in a cultured human umbilical vein endothelial cell model of vascular injury.

Milford E, Meital L, Kuballa A, Reade M, Russell F Intensive Care Med Exp. 2022; 10(1):34.

PMID: 35980492 PMC: 9388705. DOI: 10.1186/s40635-022-00462-7.

Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids.

Artru F, McPhail M, Triantafyllou E, Trovato F Front Immunol. 2022; 13:867261.

PMID: 35432367 PMC: 9008479. DOI: 10.3389/fimmu.2022.867261.

References

Chiba K . FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108(3):308-19. DOI: 10.1016/j.pharmthera.2005.05.002. View

Wing K, Sakaguchi S . Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2009; 11(1):7-13. DOI: 10.1038/ni.1818. View

Means C, Xiao C, Li Z, Zhang T, Omens J, Ishii I . Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007; 292(6):H2944-51. DOI: 10.1152/ajpheart.01331.2006. View

Awad A, Ye H, Huang L, Li L, Foss Jr F, Macdonald T . Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006; 290(6):F1516-24. DOI: 10.1152/ajprenal.00311.2005. View

Kimura T, Sato K, Kuwabara A, Tomura H, ISHIWARA M, Kobayashi I . Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 2001; 276(34):31780-5. DOI: 10.1074/jbc.M104353200. View

Raffai R, Loeb S, Weisgraber K . Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2004; 25(2):436-41. DOI: 10.1161/01.ATV.0000152613.83243.12. View

Raffai R, Dong L, Farese Jr R, Weisgraber K . Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci U S A. 2001; 98(20):11587-91. PMC: 58773. DOI: 10.1073/pnas.201279298. View

McManus D, Shah S, Fabi M, Rosen A, Whooley M, Schiller N . Prognostic value of left ventricular end-systolic volume index as a predictor of heart failure hospitalization in stable coronary artery disease: data from the Heart and Soul Study. J Am Soc Echocardiogr. 2008; 22(2):190-7. PMC: 2675872. DOI: 10.1016/j.echo.2008.11.005. View

Jin Z, Karliner J, Vessey D . Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008; 79(1):134-40. DOI: 10.1093/cvr/cvn065. View

10.

Belkaid Y, Rouse B . Natural regulatory T cells in infectious disease. Nat Immunol. 2005; 6(4):353-60. DOI: 10.1038/ni1181. View

11.

Jin Z, Zhang J, Huang Y, Hoover H, Vessey D, Karliner J . A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007; 76(1):41-50. DOI: 10.1016/j.cardiores.2007.05.029. View

12.

Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G . Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res. 2009; 83(2):285-93. DOI: 10.1093/cvr/cvp137. View

13.

Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G . Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012; 125(13):1652-63. DOI: 10.1161/CIRCULATIONAHA.111.044164. View

14.

Rosen H, Goetzl E . Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005; 5(7):560-70. DOI: 10.1038/nri1650. View

15.

Egom E, Ke Y, Musa H, Mohamed T, Wang T, Cartwright E . FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol. 2009; 48(2):406-14. PMC: 3102016. DOI: 10.1016/j.yjmcc.2009.10.009. View

16.

Nofer J, Bot M, Brodde M, Taylor P, Salm P, Brinkmann V . FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007; 115(4):501-8. DOI: 10.1161/CIRCULATIONAHA.106.641407. View

17.

Tao R, Hoover H, Zhang J, Honbo N, Alano C, Karliner J . Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol. 2009; 53(6):486-94. PMC: 2835551. DOI: 10.1097/FJC.0b013e3181a7b58a. View

18.

Zhang S, Picard M, Vasile E, Zhu Y, Raffai R, Weisgraber K . Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation. 2005; 111(25):3457-64. DOI: 10.1161/CIRCULATIONAHA.104.523563. View

19.

Keul P, Tolle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M . The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 27(3):607-13. DOI: 10.1161/01.ATV.0000254679.42583.88. View

20.

Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke H, Stein J . FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol. 2007; 178(4):2458-68. DOI: 10.4049/jimmunol.178.4.2458. View